Regulatory Filings • Dec 11, 2017
Regulatory Filings
Open in ViewerOpens in native device viewer
BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting
35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two
CRi and five PR were observed, and seven patients stayed on treatment for more
than four months. Three novel and proprietary predictive biomarker candidates
were identified.
Bergen, Norway, 11 Dec 2017 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company focused on developing a pipeline of first-in-class AXL
kinase inhibitors to treat multiple cancer indications, today announced that it
presented an update on the BGBC003 clinical trial (NCT02488408) with selective
AXL inhibitor BGB324 in patients with relapsed/refractory Acute Myeloid
Leukaemia (AML) or Myeloid Dysplastic Syndrome (MDS). Clinical benefit was
observed and three novel, proprietary predictive biomarker candidates were
identified. Data showing the immune modulatory effect of BGB324 in this patient
population was also reported.
In a poster presentation at the 59th American Society of Hematology Annual
Meeting in Atlanta entitled: "The orally available selective AXL inhibitor
BGB324 induces diversification of the immune repertoire and specific changes in
plasma biomarker profiles", Professor Sonja Loges, attending physician at the
University Hospital in Hamburg-Eppendorf and lead investigator of the BGBC003
trial, detailed the following:
· 35 patients with relapsed/refractory AML or MDS received BGB324 monotherapy
on the BGBC003 trial. Two patients achieved complete responses with incomplete
heamatologic recovery (CRi) and five achieved partial responses (PR). Seven
patients reported disease stabilisation for more than four months. Four patients
remain on study at the time of data cut-off.
· Three novel predictive biomarker candidates that correlated significantly
with clinical benefit were detected in blood, bone marrow plasma or bone marrow
cell samples from patients.
· Over the course of treatment with BGB324, patients demonstrated a
diversification of their T- and B-cell receptor repertoire in peripheral blood
and/or bone marrow indicating immune activation upon BGB324 therapy.
Professor Sonja Loges commented: ''Relapsed/refractory AML and MDS patients
currently have no treatment options. Selective AXL inhibition holds particular
promise as a potential new treatment modality as it blocks a key cancer survival
mechanism in the bone marrow and acts as an activator of the immune system. I am
extremely encouraged by these signs of clinical efficacy of BGB324 in these
patients as well as the favourable safety profile observed.''
Richard Godfrey, CEO of BerGenBio commented: "The BGBC003 trial in AML is one of
six ongoing phase II trials evaluating our first-in-class selective AXL
inhibitor BGB324. The observed clinical benefit with BGB324 monotherapy in AML
and MDS is very encouraging. The second part of the trial, featuring expansion
cohorts as a monotherapy as well as in combination with low dose chemotherapy is
ongoing and we are looking forward to reporting an update in 2018. I am
particularly encouraged with the biomarker data as this supports our clinical
development strategy to enrich future clinical trials with patients most likely
to benefit from therapy with BGB324''.
About AML
AML is the most common form of acute leukaemia in adults where malignant AML
blasts interfere with the normal functioning of the bone marrow leading to a
multitude of complications like anaemia, infections and bleeding. AML is
diagnosed in over 20,000 patients in the US annually and is rapidly lethal if
left untreated. Successful treatment typically requires intensive therapy or
bone marrow transplantation, and relapse and resistance are common.
Consequently, there is an urgent need for effective novel therapies in
relapsed/refractory patients, particularly those that are ineligible for
intensive therapy.
About the BGBC003 trial
The BGBC003 trial is a phase Ib/II multi-centre open label study of BGB324 as a
single agent in patients with AML or MDS or in a combination with cytarabine and
decitabine in AML patients. Up to 75 patients will be enrolled at centres in the
US, Norway, Germany and Italy. For more information please access trial
NCT02488408 at www.clinicaltrials.gov.
About the 59th ASH Annual Meeting in Atlanta, GA
The 59th ASH Annual Meeting and Exposition is the most comprehensive haematology
conference worldwide and attracts more than 25,000 haematology professionals
from every subspecialty.
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple
cancer indications. The Company is a world leader in understanding the essential
role of AXL kinase in mediating cancer spread, immune evasion and drug
resistance in multiple aggressive solid and haematological cancers.
BerGenBio's lead product, BGB324, is a selective, potent and orally bio
-available small molecule AXL inhibitor in four Company sponsored Phase II
clinical trials in major cancer indications, with read-outs anticipated in the
second half of 2018. It is the only selective AXL inhibitor in clinical
development.
The Company sponsored clinical trials are:
· BGB324 as a single agent and combination therapy in acute myeloid leukaemia
(AML) / myeloid dysplastic syndrome (MDS)
· BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small
cell lung cancer (NSCLC)
· BGB324 with KEYTRUDA in advanced adenocarcinoma of the lung, and
· BGB324 with KEYTRUDA in triple negative breast cancer (TNBC).
The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung
and TNBC are conducted in collaboration with Merck & Co., Inc., Kenilworth,
N.J., USA.
In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR®
(dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining
BGB324 with docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with BGB324. This
will facilitate more efficient registration trials and support a precision
medicine based commercialization strategy.
The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.
For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.
- Ends -
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
+47 477 54 415
Media Relations
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
[image]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.